A phase 1 study of 79 patients with relapsed and refractory CD22+ B-cell NHL was conducted to determine the maximum tolerated dose, safety, and efficacy of INO [44]. The gene discussed is CD22; the disease is B-cell non-Hodgkin lymphoma.